The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
to open the airways Corticosteroids to reduce the severity and length of the allergic reaction (e.g., methylprednisolone or hydrocortisone) Antihistamines to reduce the body's immune response ...